ProfileGDS5678 / 1419142_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 39% 38% 38% 37% 39% 39% 40% 38% 38% 38% 38% 38% 38% 38% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 12.9410439
GSM967853U87-EV human glioblastoma xenograft - Control 22.8742338
GSM967854U87-EV human glioblastoma xenograft - Control 32.8756538
GSM967855U87-EV human glioblastoma xenograft - Control 42.7805337
GSM967856U87-EV human glioblastoma xenograft - Control 52.8383339
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 12.9937839
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 22.9770340
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 32.8500138
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 42.8378738
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 12.8634538
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 22.8596938
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 32.8427538
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 42.8766938
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 52.8665738